Pregled bibliografske jedinice broj: 1132405
Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking
Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking // Journal of biomolecular structure & dynamics, 40 (2022), 19; 9347-9360 doi:10.1080/07391102.2021.1927845 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1132405 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Proposition of a new allosteric binding site for
potential SARS-CoV-2 3CL protease inhibitors by
utilizing molecular dynamics simulations and
ensemble docking
Autori
Novak, Jurica ; Rimac, Hrvoje ; Kandagalla, Shivananda ; Pathak, Prateek ; Naumovich, Vladislav ; Grishina, Maria ; Potemkin, Vladimir
Izvornik
Journal of biomolecular structure & dynamics (0739-1102) 40
(2022), 19;
9347-9360
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
3CL protease ; molecular dynamics ; SARS-CoV-2 ; radotinib ; nilotinib
Sažetak
The SARS-CoV-2 3CL protease (3CLpro) shows a high similarity with 3CL proteases of other beta- coronaviruses, such as SARS and MERS. It is the main enzyme involved in generating various non- structural proteins that are important for viral replication and is one of the most important proteins responsible for SARS-CoV-2 virulence. In this study, we have conducted an ensemble docking of molecules from the DrugBank database using both the crystallographic structure of the SARS-CoV-2 3CLpro, as well as five conformations obtained after performing a cluster analysis of a 300 ns molecular dynamics (MD) simulation. This procedure elucidated the inappropriateness of the active site for non-covalent inhibitors, but it has also shown that there exists an additional, more favorable, allosteric binding site, which could be a better target for non-covalent inhibitors, as it could prevent dimerization and activation of SARS- CoV-2 3CLpro. Two such examples are radotinib and nilotinib, tyrosine kinase inhibitors already in usefor treatment of leukemia and which binding to the newly found allosteric binding site was also confirmed using MD simulations.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Interdisciplinarne prirodne znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE